Hsbc Holdings PLC Acquires 26,284 Shares of Haemonetics Corporation $HAE

Hsbc Holdings PLC lifted its holdings in Haemonetics Corporation (NYSE:HAE) by 239.6% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 37,256 shares of the medical instruments supplier’s stock after purchasing an additional 26,284 shares during the period. Hsbc Holdings PLC owned about 0.08% of Haemonetics worth $2,097,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of HAE. Kemnay Advisory Services Inc. purchased a new position in Haemonetics during the fourth quarter valued at approximately $26,000. Leonteq Securities AG bought a new stake in Haemonetics during the 4th quarter valued at $30,000. EverSource Wealth Advisors LLC boosted its position in Haemonetics by 2,640.0% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier’s stock valued at $31,000 after acquiring an additional 396 shares in the last quarter. Kestra Advisory Services LLC bought a new stake in Haemonetics during the 4th quarter valued at $34,000. Finally, Bayforest Capital Ltd purchased a new position in shares of Haemonetics in the 4th quarter valued at $40,000. 99.67% of the stock is currently owned by institutional investors.

Haemonetics Price Performance

NYSE HAE opened at $78.56 on Monday. The firm’s fifty day simple moving average is $72.75 and its two-hundred day simple moving average is $66.06. The firm has a market capitalization of $3.57 billion, a P/E ratio of 38.89, a P/E/G ratio of 1.59 and a beta of 0.52. The company has a current ratio of 2.95, a quick ratio of 1.87 and a debt-to-equity ratio of 1.53. Haemonetics Corporation has a 12-month low of $47.31 and a 12-month high of $87.32.

Haemonetics (NYSE:HAE) last issued its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $1.29 EPS for the quarter, beating the consensus estimate of $1.28 by $0.01. The firm had revenue of $346.35 million during the quarter, compared to analyst estimates of $336.83 million. Haemonetics had a return on equity of 27.30% and a net margin of 7.29%.The business’s revenue for the quarter was up 4.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.24 EPS. Haemonetics has set its FY 2027 guidance at 5.258-5.307 EPS. Analysts forecast that Haemonetics Corporation will post 5.21 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

HAE has been the subject of several recent research reports. Weiss Ratings raised Haemonetics from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, June 25th. Barrington Research dropped their price objective on Haemonetics from $94.00 to $89.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 12th. Mizuho lifted their target price on Haemonetics from $85.00 to $90.00 and gave the company an “outperform” rating in a research note on Wednesday, July 15th. Wall Street Zen upgraded shares of Haemonetics from a “hold” rating to a “buy” rating in a report on Saturday, May 23rd. Finally, Robert W. Baird set a $67.00 price target on shares of Haemonetics in a research report on Friday, May 8th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $78.89.

About Haemonetics

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.